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Background: Auditory neuropathy spectrum disorder (ANSD) is a unique form of hearing loss that involves
absence or severe abnormality of auditory brainstem response (ABR), but also the presence of otoacoustic
emissions (OAEs). However, with age, the OAEs disappear, making it difficult to distinguish this condition from other
nonsyndromic hearing loss. Therefore, the frequency of ANSD may be underestimated. The aim of this study was to
determine what portion of nonsyndromic hearing loss is caused by mutations of OTOF, the major responsible gene
for nonsyndromic ANSD.
Methods: We screened 160 unrelated Japanese with severe to profound recessive nonsyndromic hearing loss
(ARNSHL) without GJB2 or SLC26A4 mutations, and 192 controls with normal hearing.
Results: We identified five pathogenic OTOF mutations (p.D398E, p.Y474X, p.N727S, p.R1856Q and p.R1939Q) and
six novel, possibly pathogenic variants (p.D450E, p.W717X, p.S1368X, p.R1583H, p.V1778I, and p.E1803A).
Conclusions: The present study showed that OTOF mutations accounted for 3.2–7.3% of severe to profound
ARNSHL patients in Japan. OTOF mutations are thus a frequent cause in the Japanese deafness population and
mutation screening should be considered regardless of the presence/absence of OAEs.
Keywords: Auditory neuropathy spectrum disorder, DFNB9, Nonsyndromic hearing lossBackground
Auditory neuropathy (AN), a unique form of hearing
loss, involves absence or severe abnormality of auditory
brainstem response (ABR), but presence of otoacoustic
emissions (OAE) and/or cochlear microphonic (CM). This
disorder was defined by Starr [1], and also reported as
“Auditory nerve disease” [2] and “Auditory dys-synchrony”
[3]. AN was renamed “auditory neuropathy spectrum
disorder (ANSD)” in 2008, due to the heterogeneous
and multifaceted nature [4].
The prevalence of ANSD in sensorineural hearing loss
is reported to be 0.5-15% [5]. The etiologies of ANSD
are various; patients range from infants to adults, 42% of
which are associated with hereditary neurological disor-
ders, 10% with toxic, metabolic, immunological and infec-
tious causes, and 48% with unknown causes [6]. Although* Correspondence: usami@shinshu-u.ac.jp
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reproduction in any medium, provided the orthe exact percentage of nonsyndromic ANSD is unclear,
responsible genes have been gradually revealed. To date,
mutations of AUNA1, OTOF, PJVK, GJB2 and mito-
chondrial 12S rRNA are reported to be causal for
nonsyndromic ANSD [7].
The OTOF gene (DFNB9) is mainly expressed in
cochlear inner hair cells, and is necessary for synaptic
exocytosis at the auditory ribbon synapse [8]. It encodes
both long and short isoforms with the long isoform
containing six C2 domains and the C-terminal trans-
membrane domain, and the short isoform containing
only the last three C2 domains [9]. Mutations in the
OTOF gene, encoding otoferlin, are reported to be the
major causes of nonsyndromic recessive ANSD [10-12]. In
Japanese, mutations in OTOF account for 56. 5% (13/23)
of ANSD [13]. Although ANSD can be characterized by
the presence of OAEs in the first two years of life, OAEs
later disappear and the hearing loss then resembles
other types of nonsyndromic hearing loss [14]. Because
of expected good outcomes of cochlear implantation fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to perform mutation screening for OTOF to select the
appropriate intervention. Although some reports have
described OTOF mutations in severe to profound auto-
somal recessive hearing loss patients in other populations
[11,12], there has been no literature available regarding
the screening of OTOF mutations using a large cohort in a
comprehensive manner. The goal of this study was there-
fore to reveal the frequency of ANSD and to identify
OTOF mutations in Japanese ARNSHL patients.
Methods
Subjects
Among the 1511 Japanese independent hearing loss
patients registered in our DNA sample bank, 469 were
congenital severe to profound sensorineural hearing loss
(above 71 dB average over 500, 1000, 2000 and 4000 Hz
in the better hearing ear) patients compatible with auto-
somal recessive inheritance (including sporadic cases).
From those, we randomly selected 160 patients. All
ANSD cases were sporadic (compatible with autosomal
recessive inheritance). They were diagnosed as ANSD by
evaluation of OAE response. We excluded autosomal
dominant families because in previous studies OTOF
mutations were not found in such groups [17]. Pure tone
audiometry was used for adults (N= 32) and ABR, audi-
tory steady-state responses (ASSR), and conditioned
orientation response audiometry (COR) were used for
pediatric patients (n=128). The control group was com-
posed of 192 unrelated Japanese individuals who had
normal hearing shown by auditory testing. All subjects
gave prior informed written consent for participation
in the project and the Ethical Committee of Shinshu
University approved the study.
Mutation analysis
We designed 43 pairs of primers to amplify DNA frag-
ments containing all exons in the coding regions of the
OTOF gene (ENST00000403946). Primer3Plus (http://
www.bioinformatic.nl/cgi-bin/primer3plus/primer3plus.
cgi) was used to design primers to flank all the exon-
intron boundaries. Each genomic DNA sample (40 ng) was
amplified, using Ampli Taq Gold (Applied Biosystems,
Foster City, CA), for 5 min at 95°C, followed by 30 three-
step cycles of 95°C for 30s, 60°C for 30s, and 72°C for 60s,
with a final extension at 72°C for 7 min, ending with a
holding period at 4°C in a PCR thermal cycler (Takara,
Shiga, Japan). PCR products were treated with ExoSAP-IT®
(GE Healthcare Bio, Santa Clara, CA) by incubation at
37°C for 60 min, and inactivation at 80°C for 15 min.
After the products were purified, we performed stand-
ard cycle-sequencing reactions with ABI Big Dye® termi-
nators in an ABI PRISM 3100 Genetic Analyzer
autosequencer (Applied Biosystems, Foster City, CA).Computer analysis to predict the effect of missense vari-
ants on the protein function was performed with
wANNOVAR [18-20] (http://wannovar.usc.edu) including
functional prediction software listed below. PhyloP (http://
hgdownload. cse.ucsc.edu/goldenPath/hg18/phyloP44way/),
Sorting Intolerant from Tolerant (SIFT; http://sift.jcvi.org/),
Polymorphism Phenotyping (PolyPhen2; http://genetics.
bwh.harvard.edu/pph2/), LRT (http://www.genetics.wustl.
edu/jflab/lrt_query.html), and MutationTaster (http://
www.mutationtaster.org/).
Results
We found a total of 11 probable pathogenic variants in the
patients (Table 1). Among them, five mutations were previ-
ously reported: p.D398E, p.Y474X, p.N727S, p.R1856Q and
p.R1939Q. The other six probable pathogenic variants
were novel: 2 nonsense mutations (p.W717X, p.S1368X)
and 4 missense mutations (p.D450E, p.R1583H, p.V1778I,
p. E1803A). Based on the prediction programs, it is most
likely that p.D450E (c.1350C>G), p.R1583H (c.4748G>A),
p.V1778I (c.5332G>A), and p.E1803A (c.5408A>C) were
pathogenic. In addition, they were absent (or in very few
numbers) in the controls, and located in C2 domains,
which are highly conserved among species (Figure 1). In
addition, polymorphic changes were also identified
(Table 2). p.R1676C (c.5026C>T) was previously reported
to be pathogenic [21], but we excluded p.R1676C as it is
unlikely to be pathologic because of high frequencies in
the control population (Table 2). Among the 16 patients
with OTOF mutations, 4 were homozygous, 3 were com-
pound heterozygotes, and 9 were heterozygous without
second mutation (Table 3). After clinical re-evaluation, we
recategorized cases with OAE as ANSD.
Discussion
So far, more than 90 pathologic mutations have been
reported in OTOF [25]. The present study identified 11
possibly pathogenic OTOF variants in Japanese pa-
tients with nonsyndromic hearing loss, and 6 of them
were novel mutations (p.D450E, p.W717X, p.S1368X,
p.R1583H, p.V1778I, and p.E1803A). Concerning patho-
genicity of the four novel missense mutations, p.R1583H
is more likely to be a disease causing mutation, because
1) it was found in compound heterozygosity with p.R1939Q,
2) it was absent in controls, 3) it affects a C2 domain, and
4) the scores provided by prediction programs also agree
with the pathogenicity. The pathogenic potential of the
three other variants (p.D450E, p.V1778I, and p.E1803A) is
less clear, because 1) all of them have been found in the
heterozygous state without accompanying mutation in the
other allele, and 2) p.D450E was found in controls. But it
is also true that 1) they affect C2 domains, and 2) the
scores of the prediction programs would support their
classification as pathogenic variants.
Table 1 Probable pathogenic and uncertain pathogenic variants of OTOF identified in this study








PhyloP SIFT (p-value) P2 D.S. LRT Mutation taster GERP ++
Probable pathogenic variants
Exon 14 c.1422T>A p.Y474X 2/320 0/374 N (0.072941) NA (0.829813) NA (0.58309) D (1) A (1) −3.78 [13]
Exon 18 c.2151G>A p.W717X 1/320 0/344 C (0.994764) NA (0.90345) NA (0.734698) D (0.999998) A (1) 3.83 This study
Exon 34 c.4103C>G p.S1368X 1/320 0/364 N (0.944413) NA (0.915) NA (0.554899) NA (0.026679) A (1) 0.571 This study
Exon 38 c.4748G>A p.R1583H 1/320 0/366 C (0.997935) D (1) D (0.999) D (1) D (0.999661) 4.69 This study
Exon 44 c.5567G>A p.R1856Q 1/320 0/380 C (0.99611) T (0.91) P (0.813) D (1) D (0.999517) 4.1 [11]
Exon 46 c.5816G>A p.R1939Q 11/320 0/382 N (0.996658) T (0.92) NA (0.746672) NA (1) D (0.999886) 1.38 [22]
Uncertain pathogenic variants
Exon 12 c.1194T>A p.D398E* 1/320 1/380 N (0.232793) T (0.77) D (0.853) D (1) D (0.995165) 0.981 [23]
Exon 13 c.1350C>G p.D450E* 1/320 1/380 C (0.986229) T (0.74) D (0.853) D (1) D (0.991594) 3.54 This study
Exon 18 c.2180A>G p.N727S* 2/320 1/344 C (0.992986) T (0.27) P (0.386) D (1) D (0.95528) 3.98 [21]
Exon 43 c.5332G>A p.V1778I 1/320 0/378 C (0.997116) T (0.54) P (0.289) D (1) D (0.994783) 4.38 This study
Exon 43 c.5408A>C p.E1803A 1/320 0/378 C (0.994555) D (1) D (0.995) D (1) D (0.999914) 4.26 This study
*the variants found in controls.
Exon number was named based on ENST00000403946.
A, disease causing automatic; C, conserved; D, damaging or disease causing; N, not conserved; NA, not applicable; P, possibly damaging; T, tolerated; P2 D.S., Polyphen-2 damaging score. Polyphen-2, PhyloP, LRT,
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Figure 1 The location of mutations in otoferlin protein and the evolutionary conservation of the amino acids. (A) Evolutionary
conservation. The locations of mutations are boxed. (B) Novel pathogenic OTOF mutations found in this work and relation to the functional
domains of otoferlin. C2A-F: C2 domains. TMD: transmembrane domain.
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found in the Japanese population was quite different
from those reported in Caucasians [13,26-28].
With regard to recurrent mutations, p.Q829X especially
has a high frequency in Spanish people, being present in
about 3% of all cases of recessive prelingual deafness [24].
C.2905-2923delinsCTCCGAGCGGCA is also common in
Argentineans [12] and p.E1700Q is reported to be fre-
quent in Taiwanese [29]. p.R1939Q, previously identified
in the United States [22] and most recently reported as a
frequent mutation in Japanese [13], was also frequentlyTable 2 Non-pathogenic variants of OTOF identified in this st
Exon DNA level Protein level Occurrence in this
Exon 3 c.145C>T p.R49W 5/320
Exon 3 c.157G>A p.A53T 2/320
Exon 3 c.158C>T p.A53V 42/320
Exon 4 c.244C>T p.R82C 14/320
Exon 21 c.2452C>T p.R818W 1/320
Exon 40 c.5026C>T p.R1676C 1/320found in this study. Among 160 patients, 8 (5.0%) had this
mutation, confirming it is indeed a recurrent mutation in
Japanese.
Those recurrent mutations have been proved to be
due to founder effects [13,24,29].
Out of 16 patients with OTOF mutations, 7 showed
ANSD phenotype, confirming that OTOF mutations are
major causes of ANSD. In this study, 9 were heterozygous
without second mutation. A hallmark of recessive muta-
tions is the detection of two mutations in the paternal and
maternal alleles and the parents having normal hearing.udy







Table 3 Patients who have at least one pathogenic mutation identified in this study
Patient DNA level Protein level Clinical diagnosis OAE Age at diagnosis Hearing loss level
1 c.1422T>A / c.5567G>A p.Y474X / p.R1856Q ANSD + 1y6m Profound
2 c.1422T>A / c.5816G>A p.Y474X / p.R1939Q ANSD + NA Profound
3 c.5816G>A / c.5816G>A p.R1939Q / p.R1939Q ANSD + 4m Profound
4 c.5816G>A / c.5816G>A p.R1939Q / p.R1939Q ANSD + 10m Profound
5 c.5816G>A / c.5816G>A p.R1939Q / p.R1939Q ANSD + NA Profound
6 c.4748G>A / c.5816G>A p.R1583H / p.R1939Q NSHL NA 6m Profound
7 c.2151G>A / c.5816G>A p.W717X / p.R1939Q NSHL - 1y4m Profound
8 c.5816G>A / - p.R1939Q /- ANSD + 1y5m Profound
9 c.5816G>A / - p.R1939Q /- ANSD + 7m Profound
10 c.1194T>A / - p.D398E / - NSHL NA NA Profound
11 c.1350C>G / - p.D450E / - NSHL NA 2y Severe
12 c.2180A>G / - p.N727S / - NSHL NA 6m Profound
13 c.2180A>G / - p.N727S / - NSHL NA 1y Severe
14 c.4103C>G / - p.S1368X / - NSHL NA 7m Profound
15 c.5332G>A / - p.V1778I / - NSHL NA NA Profound
16 c.5408A>C / - p.E1803A / - NSHL NA 4m Profound
ANSD Auditory neuropathy spectrum disorder, NSHL Nonsyndromic sensorineural hearing loss.
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those for OTOF [12,23,30], there were a significant num-
ber of heterozygous cases without a second mutation even
after direct sequencing of the coding region of the gene.
Possible explanations are: 1) the existence of a second mu-
tation in the intron or regulatory region of OTOF, which
has not been explored, 2) the existence of a large deletion
[31], 3) contribution to hearing loss by an additional
modulatory gene, and 4) the existence of a mutation in
another gene and just coincidental carrying of the
OTOF mutation.
As seen in Table 3, two heterozygous patients (#8, 9)
having the ANSD phenotype, are most likely to have
OTOF related deafness.
It is assumed that OTOF mutations accounted for
deafness in at least 7, and possibly 16, of the 160 pa-
tients (4.4-10.0%). As described in the subject section,
we excluded the subjects carrying GJB2 and SLC26A4
mutations. We also excluded another responsible gene
(PJVK), because no mutations in this gene were found.
Since the frequencies of GJB2 and SLC26A4 gene muta-
tions among the patients with nonsyndromic severe to
profound congenital SNHL are 27.0% based on our
database, mutation frequency of OTOF among the total
of severe to profound recessive nonsyndromic SNHL is
considered to be about 3.2-7.3% (which is calculated by
((7-16)/160×(100/73))×100%). Although simple com-
parison regarding frequency is difficult because of sam-
pling bias, it is estimated that the frequency of OTOF
mutations in Japanese may be almost equal to other
populations, as mutation frequency of OTOF wasreported at 2.3% (13/557) in Pakistanis [11], 5.0% in
Turkish [32], 1.4% (1/73) in Chinese [23], and 18.2% (4/
22) in Taiwanese [29], and 3.2% (23/708) in Spanish [12].
Although simple comparison regarding frequency is diffi-
cult because of sampling bias, it is estimated that the fre-
quency of OTOF mutations in Japanese may be almost
equal to other populations. In Japanese, GJB2, SLC26A4,
CDH23 and the 1555A>G mutation in the mitochon-
drial 12S rRNA are the major causes of hearing loss
[33]. Considering the frequency, the OTOF gene may be
one of the candidate genes to be screened for recessive
severe to profound recessive SNHL.
The benefits of cochlear implantation for patients with
ANSD has varied [34,35], but implantation has been
shown to be effective for the patients with OTOF muta-
tions [15,16,36], because their auditory nerves and spiral
ganglions are preserved. Consequently, if an OTOF mu-
tation is identified in a deaf patient, we can anticipate a
good outcome of cochlear implantation, therefore, it is
important and meaningful to identify genetic mutations
in patients.
Most patients with OTOF mutations have a phenotype
of stable prelingual and severe to profound nonsyndromic
hearing loss. On the other hand, other phenotypes have
also been reported. For example, a Taiwanese patient with
an p.E1700Q mutation displayed moderate to profound
progressive hearing loss [29]. Temperature sensitive
ANSD, a particular form of ANSD, has also been reported
in some populations [10,23,37].
In the very young child, electrophysiological testing
may indicate that OTOF-related deafness is ANSD, but
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results are more in accord with the findings of cochlear
lesions [14]. Therefore, if OAE is not tested at a very
early age, patients with OTOF mutations are not deemed
to have ANSD (i.e., hidden ANSD). In fact, 9 out of our
16 patients were diagnosed genetically as nonsyndromic
sensorineural hearing loss (NSHL). According to the
present data, screening for OTOF is necessary not only
for the patients diagnosed with ANSD, but also should
be extended to ARNSHL cases. The current data indi-
cated that OAE testing must always be conducted in
addition to ABR in infants. And we should bear in mind
that there may be patients with OTOF mutations among
the patients diagnosed as having ARNSHL.
Conclusions
The present study showed that OTOF mutations accounted
for 3.2-7.3% of recessive severe to profound SNHL pa-
tients in Japan. OTOF mutations are a frequent cause in
the Japanese deafness population and mutation screening
should be considered regardless of the presence/absence
of OAEs.
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